Certifications
- Institute for Functional Medicine Certified Practitioner
- American Board of Physician Specialties Diplomate of the American Board of Integrative Medicine
- Academy of Integrative Health and Medicine, Diplomate
- American Board of Family Medicine:Board Certification
- Diplomate of the American Board of Family Medicine
- Fellow of the American Academy of Family Medicine
Aaron Hartman MD
Dr. Hartman's Story
Dr. Hartman’s interest in integrative & functional medicine first began after he and his wife Rebekah adopted their first daughter Anna in 2007. The medical system didn’t offer much hope for Anna’s medical condition and they were forced to explore alternative treatments. Over time, Aaron began to apply the new concepts and treatment modalities he was learning to his clinic patients as well as his own family. In 2012 he formalized his commitment to exploring new and advanced treatment opportunities through his membership with the American Board of Integrative and Holistic Medicine and then the Institute for Functional Medicine. In 2015 he received his second board certification in Integrative and Holistic Medicine through the American Board of Physician Specialties and in 2016 earned the recognition as a Certified Practitioner in Functional Medicine from the Institute for Functional Medicine.
In 2012, Aaron and Rebekah’s commitment to their family’s health led them to move to a little farm outside of Richmond Virginia. While researching how to care for their land, animals, and livestock, Aaron and Rebekah learned about the intricate connections between their health, that of the land they cultivate, the animals they care for, and the food they eat. This led to Dr. Hartman’s intense interest in nutritional medicine as well as ecological medicine and toxicology.
Dr. Hartman opened Richmond Integrative & Functional Medicine in 2017. His mission at RIFM is to apply the sum total of his scientific research, medical knowledge, clinical experience and continuing studies to his patients in an individualized manner. This new field of medicine has been called Functional Medicine, Integrative Medicine, Systems Biology Medicine and Root Cause Medicine. At its core is the application of the sum total of current and ongoing scientific knowledge in the context of modern medicine, allowing for the appropriate integration of other healing traditions as appropriate, in an individualized manner.
Medical Biography
1995 – 2018
Dr. Hartman graduated Summa Cum Laude in Biology from Virginia Commonwealth University in 1995, earned his MD from Medical College of Virginia in 2000, and then completed his residency in Family Medicine at the Hanover Family Practice residency program at the Medical College of Virginia in 2003. That same year he earned his first board certification in Family Medicine through the American Board of Family Medicine. In 2006 he earned the honorary degree of Fellow from the American Academy of Family Physicians and became a Diplomat of the American Board of Family Medicine.
From 2003 to 2007 Dr. Hartman served in the United States Air Force while earning the rank of Major and holding multiple command positions including Clinic Director of Kleber Clinic and medical staff member at Landstuhl Regional Medical Center in Germany. He was also Medical Director of the MacDill Air Force Base Brandon Community Clinic, and supervising physician of the MacDill AFB cardiopulmonary clinic. From 2005 to 2007 Dr. Hartman obtained additional dermatological training from both USF and the University of Miami and currently manages 95% of his dermatology patients.
Throughout this time Dr. Hartman has remained active in the local scientific community. In 2010 he started Virginia Research Center, a clinical research center which offers the most up to treatment options to his patients through FDA approved medical trials. In May 2011 he was appointed to the position of Assistant Clinical Professor in the Department of Family Medicine at Virginia Commonwealth University’s School of Medicine which he still currently holds.
Dr. Hartman’s additional medical interests include: travel medicine, dermatology, and procedural medicine. He is fluent in Spanish and enjoys traveling overseas. He has worked at hospitals in Honduras, Germany and Ecuador and clinics in Belize and Guatemala. Dr. Hartman has served on the Board of Directors for Seeds of Hope Brazil, a non-profit organization dedicated to the orphans and street children of São Paulo, Brazil. His academic interests include clinical research and theology. To date he has participated in over 30 clinical trials, published in the Lancet as well as publish his seminary thesis.
Dr. Hartman is married to Rebekah Hartman who is an Occupational Therapist and has worked with pediatric patients with special needs for several years. Rebekah and Aaron were foster parents for one of these children whom they adopted in 2007. They adopted their second daughter in 2010 and their son 2016.
Aaron Hartman MD
Curriculum Vitae
Professional Experience
2022 - present
Board Certified American Board of Anti-Aging and Regenerative Medicine
2022 - present
Fellow in Anti-Aging Metabolic and Functional Medicine
Fall 2016 – present
Richmond Integrative & Functional Medicine
Midlothian, VA
Dr. Hartman started Richmond Integrative & Functional Medicine in order to provide access to advanced integrative and functional medicine evaluations and treatments to patients in the greater Richmond Metropolitan area as well as to telemedicine consults.
Fall 2012 – present
Assistant Clinical Professor of Family Medicine
Medical College of Virginia at Virginia Commonwealth University
Richmond, VA
2010 – present
Virginia Research Center
Midlothian, VA
Dr. Hartman founded VRC as one of central Virginia’s premier clinical research centers, and currently serves as VRC’s Principle Investigator and Medical Director. To date VRC has participated in over 40 research studies as well as pivotal studies and international multi-center studies. Dr. Hartman is a Key Opinion Lead in diabetes for Novum and has published in Lancet.
2007 – present
Family Practice Associates
Midlothian, VA
Dr. Hartman joined Family Practice Medicine located at St. Francis medical center—providing comprehensive patient care 7 days a week and 24 hour call service for urgent patient need.
Oct. 2005 – Sep. 2007
New Tampa Urgent Care
Tampa, FL
Part Time Attending Physician
Provided for the urgent health care needs of a diverse patient population in the New Tampa area. Daily patient census ranges from 40-60 patients over an eight hour shift.
Responsible for coordinating care for urgent patients needing next day specialist follow up as well as emergent patients needing immediate transfer to a hospital.
Mar. 2007 – Sep. 2007
CheckUps USA
Tampa, FL
Part Time Attending Physician
Supervised two nurse practioners in a retail health clinic located in WalMart. Performed supervision, chart review, consultation, and other capacities as needed.
May 2007
Pfizer Pharmaceutical Company
Tampa, FL
Physician Consultant
Lectured and educated physicians and other health care providers on topic of specific and non-specific non-steroidal anti-inflammatories on behalf of Pfizer. Trained and approved national speaker.
Aug. 2003 – Sep. 2007
MacDill AFB Hospital
Tampa, FL
Attending Physician
Brandon Community Clinic Medical Director (May 2006 – 2007)
Duties included supervision of a clinic caring for over 11,000 beneficiaries, three physicians, three physician assistants and coordinating clinic activities with MacDill AFB while providing care for 1,400 patients.
Physician manager for Cardio/Pulmonary Clinic (2007)
Performed and oversaw treadmill stress testing, event/holter monitoring, EKG reading, pulmonary function testing , EIA/methacholine asthma testing, and 24hr ambulatory BP monitoring.
Primary Care Manager at Brandon Community Clinic (Jan 2004 – May 2006)
Managed a primary care team of one nurse and two medical technicians and caring for a patient population of 1,400 ranging from newborns to geriatrics while supervising two Physician Assistants. Served as clinic Quality Assurance Program officer for clinic. Provided after hours Emergency Department backup when needed.
Deployed to Landstuhl Regional Medical Center, Germany (Sep 2004 – Dec 2004)
Deployed in support of combat operations. Served in Deployed Warrior Medical Readiness Clinic and Kleber Clinic and was acting Clinic Director for Kleber Clinic.
Primary Care Manager (Apr 2004 – Aug 2004)
Delivered care for a diverse population of 1,300 patients ranging from infants to elderly and supervised two technicians and a nurse.
Active Duty Clinic for deploying personnel (Aug 2003 – Apr 2004)
Managed overseas related injuries and illnesses, supervised a Physician Assistant and Nurse Practitioner. Total empanelment of 4,500 patients.
Jun. 2002 – Jun. 2003
Memorial Regional Medical Center
Mechanicsville, VA
Staff Physician
Served as Emergency Physician backup for in-hospital, non-ED emergencies. Performed backup services in hospital during after-hours and weekends.
Professional Memberships
American Academy of Family Physicians
Uniformed Services Academy of Family Physician
Diplomate of the American Board of Family Medicine
Diplomate of the American Association of Physician Specialists
Fellow in Anti-Aging Metabolic and Functional Medicine
Diplomate of American Board of Integrative Medicine
Diplomate of Academy of Integrative Health and Medicine
Institute for Functional Medicine Certified Practitioner
Board Certified American Board of Anti-Aging and Regenerative Medicine
Education
2019 – 2021
Fellowship in Anti-Aging Metabolic and Function Medicine
American Academy of Anti-Aging Medicine
in association with Georgetown University
2013 – 2015
Certification in Functional Medicine
Institute for Functional Medicine
2004 – 2010
Master of Arts and Religion
Reformed Theological Seminary
Charlotte, NC
Thesis published with Deep River Books in 2012
2001 – 2003
Family Practice Residency
Hanover Family Practice Residency at the Medical College of Virginia
Mechanicsville, VA
2000 – 2001
Medicine/Surgery Internship
Medical College of Virginia Hospitals
Richmond, VA
1996 – 2000
Medical Doctorate
Medical College of Virginia, School of Medicine
Richmond, VA
1991 – 1995
Bachelor of Science, Biology
Virginia Commonwealth University
Richmond, VA
Certifications & Licensing
2022- present
Fellow of the Academy of Anti-Aging Metabolic and Functional Medicine
2022- present
Board Certified American Board of Anti-Aging and Regenerative Medicine
2022- present
Fellow in Anti-Aging Metabolic and Functional Medicine
April 2016 - present
Institute for Functional Medicine Certified Practitioner
November 2015 – present
American Board of Physician Specialties Diplomate of the American Board of Integrative Medicine
November 2012 – present
Academy of Integrative Health and Medicine, Diplomate
July 2003 – present
American Board of Family Medicine Certification
November 2007 – present
Virginia State License
February 2006 – February 2008
Pediatric Advanced Life Support
2003 – 2007 (annual)
Nuclear, Chemical, Biological Warfare Certification
October 2003 – October 2007
Advanced Trauma Life Support
October 2003 – October 2007
Combat Care Casualty Coarse for Hospital Deployment
2003 – 2007 (annual)
Medical Warfare Response Certification
August 2005 – January 2008
Florida State License
June 2006 – June 2010
Advanced Cardiac Life Support
September 2007 – 09 September 2009
Basic Life Support
Activities & Honors
Fellow of the Academy of Anti-Aging Metabolic and Functional Medicine
Fellow of the American Academy of Family Physicians
Diplomate of the American Board of Family Medicine
Diplomate of American Board of Integrative Medicine
Worked at Hospital Loma de Luz in Belfate, Honduras March 2006
Worked at Hospital Voz Andes in Shell, Ecuador, S.A. February 2003
Board Member of Seeds of Hope Sao Paolo, Brazil.
Community work at Lar Escola Pequeno Leão in Sao Paulo, Brazil, S.A.
Water tank construction project in Chiapas, Mexico, C.A.
Letter of Commendation for outstanding performance at Kleber Clinic during medical operations at the 6th Medical Operations Squadron 2004.
Languages
Spanish (Foreign Language certification)
Koine Greek
Research Accomplishments
Publications
Clinical Research Activities
2021
“A Double-Blinded, Placebo-controlled, Double Dummy, Multicenter Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Two or Three Oral Glucose lowering Agents.”
“A PHASE 1/2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY INDIVIDUALS”
2020
“A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)”
“24-Hour Ambulatory Blood Pressure Monitoring Study in Hypogonadal Men Receiving Testosterone Replacement Therapy”
2019
“A 24 –week multi-center, double-blind, placebo controlled dose-range finding study to investigate the efficacy and safety of oral QBW251 in COPD patients on triple inhaled therapy (LABA/LAMA/ICS)”
“A PHASE 3, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER”
“A long term extension trial of the Phase III lipid-lowering trials to assess the effect of long term dosing of inclisiran given as subcutaneous injections in subjects with high cardiovascular risk and elevated LDL-C (ORION-8)”
“A Randomized, Blinded, Multiple-Dose, Placebo-Controlled, Multi-Center Study Comparing Beclomethasone Dipropionate HFA Inhalation Aerosol, 40 mcg to QVAR® 40 mcg (beclomethasone dipropionate HFA), Inhalation Aerosol in Treatment of Subjects with Asthma”
“An Open-label, 52-Week, Multicenter Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-Release Tablets in Adults with Attention-Deficit/Hyperactivity Disorder”
“A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group Trial Evaluating the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults with Attention-deficit/Hyperactivity Disorder”
2018
”SELECT - Semaglutide effects on cardiovascular outcomes in people with overweight or obesity”
“A randomized, multiple-dose, parallel group design consisting of a singleblinded 2-week placebo Run-in Period followed by an investigator-blinded 4-week Treatment Period with placebo, test product (generic fluticasone propionate 100 µg and salmeterol xinafoate 50 µg inhalation powder), or reference product (Advair 100/50)”
“A Randomized, Double-Blind, Parallel Group, Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistent Asthma”
“A PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED TRIAL TO EVALUATE THE EFFECT OF 300 MG OF INCLISIRAN SODIUM GIVEN AS SUBCUTANEOUS INJECTIONS IN SUBJECTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD) AND ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C)”
“Testosterone Replacement Therapy for Assessment of Long-Term Vascular Events and Efficacy ResponSE in Hypogonadal Men (TRAVERSE) Study”
“A Phase 3, Prospective, Double-Blinded, Randomized Controlled Trial Of The Micronized dHACM Injection As Compared To Saline Placebo Injection In The Treatment Of Achilles Tendonitis”
2017
“A Phase 3, Placebo-controlled, Randomized, Observer-blinded Study To Evaluate The Efficacy, Safety, And Tolerability Of A Clostridium Difficile Vaccine In Adults 50 Years Of Age And Older”
“A trial comparing the efficacy and safety of insulin degludec and insulin glargine 300 units/mL in subjects with type 2 diabetes mellitus inadequately treated with basal insulin with or without oral anti-diabetic drugs.”
“A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO AND ACTIVE CONTROLLED, MULTICENTER, PARALLEL GROUP STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB IN ADULT SUBJECTS WITH CHRONIC LOW BACK PAIN”
2016
”A 38 week trial comparing effect and safety of insulin degludec/insulin aspart vs. insulin glargine plus insulin aspart in subjects with type 2 diabetes treated with basal insulin with or without oral antidiabetic treatment in need of treatment intensification.”
“DUAL™ Vlll - Durability; A 104 week clinical trial comparing long term glycaemic control of insulin degludec/liraglutide (IDegLira) versus insulin glargine ttierapy in subjects witti type 2 diabetes mellitus”
2015
“DUAL™ VII — A clinical trial comparing efficacy and safety of insulin degludec/liraglutide (IDegLira) vs basal-bolus therapy in subjects with type 2 diabetes mellitus”
“A Randomized, Double-Blind, Multi-Center, Parallel Group Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 on COPD Exacerbations over a 52-Week Treatment Period in Subjects With Moderate to Very Severe COPD”
“A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to assess cardiovascular outcomes following treatment with ertugliflozin (MK-8835/PF-04971729) in subjects with Type 2 Diabetes Mellitus and Established vascular disease”
“Phase 3 Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Evaluation of the Efficacy, Safety, and Tolerability of Bococizumab (PF-04950615), In Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects”
“14-181-08 A Phase 3 Multicenter, Open-Label, 52-Week Study to Evaluate the Long-Term Safety and Tolerability of NKTR-181 in Subjects with Moderate to Severe Chronic Low Back Pain or Chronic Noncancer Pain.”
“14-181-07 A Phase 3 Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NKTR-181 in Opioid-Naïve Subjects with Moderate to Severe Chronic Low Back Pain.”
2014
“A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout”
“A 52-Week, Multicentre, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents with Asthma Inadequately Controlled on Inhaled Corticosteroid and Long-Acting ?2-Agonist (D2210C00008)
“A Long-Term Extension Study of Lesinurad in Combination with Allopurinol for Subjects Completing an Efficacy and Safety Study of Lesinurad and Allopurinol”
2013
“A Randomized, Double-blind, Double-dummy, Placebo-controlled, Active-controlled, Parallel-group, Multicenter Trial of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess the Analgesic Efficacy (Compared to Placebo) and the Management of Opioid-induced Constipation (Compared to Oxycodone Controlled-release Tablets (OXY)) in Opioid-experienced Subjects with Moderate to Severe Chronic Low Back Pain and a History of Opioid-induced Constipation who Require Around-the-clock Opioid Therapy”
“A Long-Term Extension Study of Lesinurad in Combination with Allopurinol for Subjects Completing an Efficacy and Safety Study of Lesinurad and Allopurinol”
“A Placebo-Controlled, Randomized, Double-Blind, Parallel-Group, Dose-Finding Trial to Evaluate the Efficacy and Safety of TBS-2 Intranasal Testosterone Gel in Women With Acquired Female Orgasmic Disorder”
“A trial comparing cardiovascular safety of insulin degludec versus insulin glargine in subjects with type 2 diabetes at high risk of cardiovascular events”
“Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination with Insulin Glargine and Metformin in Adults with Type 2 Diabetes”
“Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase IV Study to Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and COPD Exacerbations in Patients with Moderate to Very Severe COPD (ASCENT COPD)”
“A Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study to Evaluate the Long-term Safety of Naldemedine for the Treatment of Opioid-induced Constipation in Subjects with Nonmalignant Chronic Pain Receiving Opioid Therapy”
“A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of RDEA3170 Monotherapy in Subjects With Gout”
“A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel Design Study Comparing Clindamycin 1%/ Benzoyl Peroxide 5%Topical Gel (Taro Pharmaceuticals, Inc.) to Benzaclin ® Topical Gel Clindamycin1%/ Benzoyl Peroxide 5% (Sanofi Aventis) in the Treatment of Acne Vulgaris”
“A multi-center, randomized, double-blind, double-dummy, parallel-group dose-finding study to evaluate the change in HbA1c after 12 weeks monotherapy with seven doses of LIK066 compared with placebo or sitagliptin in patients with type 2 diabetes”
“A 28-Week, Multi-Center, Randomized, Double-Blind, Parallel-Group, Active-Controlled Safety Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® as an Active Control”
“A Randomized, Double-Blind (Test Products and Placebo), Chronic Dosing (24 Weeks), Placebo-Controlled, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo”
“A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel Design Study Comparing Diclofenac Sodium Gel 3% (Actavis) to Solaraze ® (diclofenac sodium) Gel 3% (Fougera Pharms) in the Treatment of Actinic Keratosis”
“A Phase III Randomized Double-Blind Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide and Nitazoxanide plus Oseltamivir in the Treatment of Acute Uncomplicated Influenza”
2012
“A multi-center, randomized, double-blind, 52-week study to assess the safety of QVA149 compared to QAB149 in patients with Chronic Obstructive Pulmonary Disease (COPD) who have moderate to severe airflow limitation”
“A Phase 3 Randomized, Double-Blind, Multicenter, Placebo-Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Allopurinol Compared to Allopurinol Alone in Subjects with Gout who have had an Inadequate Hypouricemic Response to Standard of Care Allopurinol”
“The effect of liraglutide versus placebo when added to basal insulin analogues with or without metformin in subjects with type 2 diabetes.”
“A Clinical Outcomes Study to compare the effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease (COPD) and a history of or at increased risk for cardiovascular disease”
“An 8-week randomized, open label, multi-center study to study to evaluate the efficacy and safety of oral aliskiren 300 mg once daily under light meal versus fasted condition in patients with hypertension”
“A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome”
“A Randomized, Double-blind, Placebo-controlled, Multicenter Trial with an Enriched Study Design to Assess the Efficacy and Safety of Oxycodone/Naloxone Controlled-release Tablets (OXN) Compared to Placebo in Opioid-experienced Subjects with Moderate to Severe Pain due to Chronic Low Back Pain who Require Around-the-clock Opioid Therapy”
“Prospective Observational Study to Evaluate Persistence With Prolia®(Denosumab) in Postmenopausal Women With Osteoporosis in Routine Clinical Practice”
“SAS115359, a Safety and Efficacy Study of Inhaled Fluticasone Propionate/ Salmeterol Combination versus Inhaled Fluticasone Propionate in the Treatment of Adolescent and Adult Subjects with Asthma”
2012 “A 6-month safety and benefit study of inhaled fluticasone propionate/ salmeterol combination versus inhaled fluticasone propionate in the treatment of 6,200 pediatric subjects 4-11 years old with persistent asthma”
2011
“A Randomized, Double-Blind, Placebo-Controlled Study to Explore Dose Effect and Frequency of Administration of AMG 151 in Subjects with Type 2 Diabetes Mellitus”
“A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Site Study to Evaluate the Clinical Equivalence of Diclofenac Sodium 1% Gel (Anchen Pharmaceuticals, Inc.) with Voltaren® Gel (diclofenac sodium topical gel) 1% (Novartis) in Patients with Osteoarthritis of the Knee”
“A Multicenter, Randomized, Placebo-controlled, Double blinded Study of the Efficacy and Safety of Lubiprostone in Subjects with Opioid-induced Bowel Dysfunction”
“A 36-week open-label extension study of CACZ885H2361 on the safety and tolerability of canakinumab 150 mg s.c. pre-filled syringe (PFS) in treating acute gouty arthritis flares in frequently flaring patients”
“A randomized, double-blind, active-controlled study of canakinumab (ACZ885) pre-filled syringes or reconstituted lyophilizate versus triamcinolone acetonide for treating acute gouty arthritis flares in frequently flaring patients”
2010
“A Randomized, Double-Blind, Placebo Controlled Study of Nitazoxanide in Adults and Adolescents with Acute Uncomplicated Influenza”
“TECOS: A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control”
“A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Study to Assess Efficacy and Safety of AKR-963 Therapy in Subjects with Severe Hypertriglyceridemia”
“The PROMISE Trial — Prospective Multicenter Imaging Study for Evaluation of Chest Pain”
2010 “A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients with Type 2 Diabetes”